Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RiNG: Niraparib and Re-irradiation in Recurrent Glioblastoma
NCT05666349Phase 1Withdrawn
- Sponsor
- University College London
- Start
- Oct 2023
- Primary completion
- Oct 2023
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of niraparib in glioblastoma (GBM), sponsored by University College London. Primary endpoint: Dose Limiting Toxicity at 28 days. Planned start Oct 2023; status: withdrawn.
02
Drugs
niraparib
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT05666349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05666349.